Tau-based therapies in neurodegeneration: opportunities and challenges

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492 · see citing works

Staging of alzheimer's disease-related neurofibrillary changes

Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · see citing works

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · see citing works

Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure

Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127 · see citing works

Blood-brain barrier breakdown in the aging human hippocampus

Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · see citing works

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · see citing works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · see citing works

Self-propagation of pathogenic protein aggregates in neurodegenerative diseases

Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · see citing works

Primary age-related tauopathy (PART): a common pathology associated with human aging

Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · see citing works

Propagation of Tau Pathology in a Model of Early Alzheimer's Disease

de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427 · see citing works

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

Ittner, L. M., & Götz, J. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2967 · Cited by 1,357 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

PET Imaging of Tau Deposition in the Aging Human Brain

Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works

A three-dimensional human neural cell culture model of Alzheimer’s disease

Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · see citing works

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · see citing works

Differential Regulation of Dynein and Kinesin Motor Proteins by Tau

Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012 · see citing works

Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9

Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951 · see citing works

Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy

Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949 · see citing works

The many faces of tau

Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · see citing works

Neuronal activity enhances tau propagation and tau pathology in vivo

Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rilett, K., Sanders, D. W., Cook, C., Fu, H., Boonen, R. A. C. M., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4328 · Cited by 820 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads

Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 773 · see citing works

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04391.x · Cited by 759 · see citing works

Brain homogenates from human tauopathies induce tau inclusions in mouse brain

Clavaguera, F., Akatsu, H., Fraser, G. M., Crowther, R. A., Frank, S., Hench, J., Probst, A., Winkler, D. T., Reichwald, J., Staufenbiel, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301175110 · Cited by 750 · see citing works

Tau protein function in living cells.

Drubin, D. G., & Kirschner, M. W. (1986) · The Journal of Cell Biology · doi:10.1083/jcb.103.6.2739 · Cited by 745 · see citing works

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · see citing works

The acetylation of tau inhibits its function and promotes pathological tau aggregation

Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · see citing works

The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein

Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721 · see citing works

Proteopathic tau seeding predicts tauopathy in vivo

Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696 · see citing works

Aβ Oligomers Cause Localized Ca ²⁺ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines

Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · see citing works

Animal models of Alzheimer's disease and frontotemporal dementia

Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · see citing works

Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice

Rhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Dröse, S., Brandt, U., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905529106 · Cited by 655 · see citing works

Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease

Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649 · see citing works

Tau and tauopathies

Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609 · see citing works

Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain

Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595 · see citing works

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · see citing works

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Ringman, J. M., Frautschy, S. A., Teng, E., Begum, A. N., Bardens, J., Beigi, M., Gylys, K. H., Badmaev, V., Heath, D. D., Apostolova, L. G., et al. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt146 · Cited by 546 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

The stress of dieting

Hutchinson, E. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn2985 · Cited by 534 · see citing works

Tau promotes neurodegeneration through global chromatin relaxation

Frost, B., Hemberg, M., Lewis, J., & Feany, M. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3639 · Cited by 519 · see citing works

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516 · see citing works

Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms

Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · see citing works

Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease

Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I.-S., Duong, D. M., Seyfried, N. T., Hu, W. T., Liu, Z., Wang, J.-Z., et al. (2014) · Nature Medicine · doi:10.1038/nm.3700 · Cited by 494 · see citing works

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

Morris, M., Knudsen, G. M., Maeda, S., Trinidad, J. C., Ioanoviciu, A., Burlingame, A. L., & Mucke, L. (2015) · Nature Neuroscience · doi:10.1038/nn.4067 · Cited by 472 · see citing works

A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity

Ahmed, Z., Cooper, J., Murray, T. K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M. A., Cavallini, A., Jackson, S., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1254-6 · Cited by 460 · see citing works

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446 · see citing works

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445 · see citing works

Reversing EphB2 depletion rescues cognitive functions in Alzheimer model

Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., Orr, A., Lotz, G., Kim, D. H., Hamto, P., et al. (2011) · Nature · doi:10.1038/nature09635 · Cited by 433 · see citing works

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · see citing works

Regional profiles of the candidate tau PET ligand ¹⁸ F-AV-1451 recapitulate key features of Braak histopathological stages

Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · see citing works

Nuclear Tau, a Key Player in Neuronal DNA Protection

Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199976 · Cited by 421 · see citing works

Disaggregation of Alzheimer β-amyloid by site-directed mAb

Solomon, B., Koppel, R., Frankel, D., & Hanan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 420 · see citing works

“Lest we forget you — methylene blue …”

Schirmer, R. H., Adler, H., Pickhardt, M., & Mandelkow�, E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.012 · Cited by 416 · see citing works

Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease

Lee, G. S., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Lana, H., Andreadis, A., Hoesen, G. W. V., & Ksiȩżak-Reding, H. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414 · see citing works

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · see citing works

Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury

Ikonomovic, M. D., Uryu, K., Abrahamson, E. E., Ciallella, J. R., Trojanowski, J. Q., Lee, V. M.-Y., Clark, R. S., Marion, D. W., Wisniewski, S. R., & DeKosky, S. T. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.06.011 · Cited by 399 · see citing works

Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo

DuBoff, B., Götz, J., & Feany, M. B. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.026 · Cited by 377 · see citing works

Antioxidants for Alzheimer Disease: A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures

Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377 · see citing works

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371 · see citing works

Does age matter? The impact of rodent age on study outcomes

Jackson, S. J., Andrews, N., Ball, D., Bellantuono, I., Gray, J., Hachoumi, L., Holmes, A., Latcham, J., Petrie, A., Potter, P., et al. (2017) · Laboratory Animals · doi:10.1177/0023677216653984 · Cited by 369 · see citing works

The CAMKK2-AMPK Kinase Pathway Mediates the Synaptotoxic Effects of Aβ Oligomers through Tau Phosphorylation

Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.003 · Cited by 351 · see citing works

Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease

Manczak, M., & Reddy, P. H. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds360 · Cited by 348 · see citing works

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., & Goedert, M. (2012) · Brain · doi:10.1093/brain/aws143 · Cited by 343 · see citing works

MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease

Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 326 · see citing works

C-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease

Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V. L., Berry, R. W., Kuret, J., & Binder, L. I. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.21.3737 · Cited by 326 · see citing works

Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52

Jo, C., Gundemir, S., Pritchard, S., Jin, Y. N., Rahman, I., & Johnson, G. V. W. (2014) · Nature Communications · doi:10.1038/ncomms4496 · Cited by 323 · see citing works

A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320 · see citing works

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320 · see citing works

Methylene Blue

Clifton, J., & Leikin, J. B. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200307000-00009 · Cited by 319 · see citing works

<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice

Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · see citing works

Antisense Reduction of Tau in Adult Mice Protects against Seizures

DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311 · see citing works

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works

The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297 · see citing works

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · see citing works

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models

van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284 · see citing works

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies

Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Brain · doi:10.1093/brain/aws013 · Cited by 281 · see citing works

PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus

Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281 · see citing works

Association of In Vivo [ 18 F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

Xia, C., Makaretz, S. J., Caso, C., McGinnis, S. M., Gomperts, S. N., Sepulcre, J., Gómez‐Isla, T., Hyman, B. T., Schultz, A. P., Vasdev, N., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5755 · Cited by 279 · see citing works

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S.-W., Li, Y., Zhou, Y., Le, D., Lo, I., Ponnusamy, R., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.005 · Cited by 277 · see citing works

Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted by Exposure to Amyloid-Beta Oligomers

Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lanté, F., & Buisson, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4261-13.2014 · Cited by 272 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

Ultrasound treatment of neurological diseases — current and emerging applications

Leinenga, G., Langton, C. M., Nisbet, R. M., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 271 · see citing works

Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner

Polanco, J. C., Scicluna, B. J., Hill, A. F., & Götz, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.709485 · Cited by 271 · see citing works

A Spatial Gradient of Tau Protein Phosphorylation in Nascent Axons

Mandell, J. W., & Banker, G. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-18-05727.1996 · Cited by 270 · see citing works

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · see citing works

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice

Ittner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., Przybyla, M., Bi, M., van Hummel, A., Stevens, C. H., et al. (2016) · Science · doi:10.1126/science.aah6205 · Cited by 263 · see citing works

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

Domı́nguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 249 · see citing works

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

Usenovic, M., Niroomand, S., Drolet, R. E., Yao, L., Gaspar, R. C., Hatcher, N. G., Schachter, J., Renger, J. J., & Parmentier-Batteur, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1523-15.2015 · Cited by 245 · see citing works

miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo

Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., Dorval, V., Parsi, S., Morin, F., Planel, E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv377 · Cited by 233 · see citing works

New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications

Chare, L., Hodges, J. R., Leyton, C. E., McGinley, C., Tan, R. H., Kril, J. J., & Halliday, G. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306948 · Cited by 230 · see citing works

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226 · see citing works

Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions

Cole, G. M., Lim, G. P., Yang, F., Teter, B., Begum, A. N., Ma, Q., Harris‐White, M. E., & Frautschy, S. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.005 · Cited by 225 · see citing works

Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia

Ittner, L. M., Fath, T., Ke, Y. D., Bi, M., van Eersel, J., Li, K. M., Gunning, P. W., & Götz, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808084105 · Cited by 223 · see citing works

Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration

Li, X., Kumar, Y., Zempel, H., Mandelkow, E., Biernat, J., & Mandelkow, E. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.376 · Cited by 222 · see citing works

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

Corre, S. L., Klafki, H., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J. M., Eriksen, J. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602913103 · Cited by 221 · see citing works

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

Collin, L., Bohrmann, B., Göpfert, U., Oroszlan‐Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 203 · see citing works

Tau Phosphorylation at Serine 396 Residue Is Required for Hippocampal LTD

Regan, P., Piers, T., Yi, J.-H., Kim, D.-H., Huh, S., Park, S. J., Ryu, J. H., Whitcomb, D. J., & Cho, K. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2842-14.2015 · Cited by 202 · see citing works

Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau

Santa‐María, I., Alaniz, M. E., Renwick, N. M., Cela, C., Fulga, T. A., Vactor, D. V., Tuschl, T., Clark, L. N., Shelanski, M. L., McCabe, B. D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78421 · Cited by 202 · see citing works

Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: The effects on the organization and stability of microtubules

Lovestone, S., Hartley, C. L., Pearce, J., & Anderton, B. H. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00126-1 · Cited by 201 · see citing works

Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau

Taniguchi-Watanabe, S., Arai, T., Kametani, F., Nonaka, T., Masuda-Suzukake, M., Tarutani, A., Murayama, S., Saito, Y., Arima, K., Yoshida, M., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1503-3 · Cited by 200 · see citing works

Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies

Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.036 · Cited by 198 · see citing works

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo

Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., Spires-Jones, T. L., Bacskai, B. J., & Hyman, B. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318807111 · Cited by 193 · see citing works

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works

Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Ke, Y. D., Delerue, F., Gladbach, A., Götz, J., & Ittner, L. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007917 · Cited by 189 · see citing works

Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs

Rocher, A. B., Crimins, J. L., Amatrudo, J. M., Kinson, M. S., Todd-Brown, M. A., Lewis, J., & Luebke, J. I. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.029 · Cited by 187 · see citing works

Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo

Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0327 · Cited by 187 · see citing works

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · see citing works

Targeting microglia for the treatment of Alzheimer’s Disease

Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185 · see citing works

Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.

Fatouros, C., Pir, G. J., Biernat, J., Koushika, S., Mandelkow, E., Mandelkow, E., Schmidt, E., & Baumeister, R. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds190 · Cited by 183 · see citing works

Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein

Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · see citing works

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · see citing works

Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin

Hu, Y., Li, X., Wang, Z.-H., Luo, Y., Zhang, X., Liu, X., Feng, Q., Wang, Q., Yue, Z., Chen, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7861 · Cited by 171 · see citing works

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 163 · see citing works

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 163 · see citing works

The role of extracellular Tau in the spreading of neurofibrillary pathology

Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury

Shultz, S. R., Wright, D. K., Zheng, P., Stuchbery, R., Liu, S.-J., Sashindranath, M., Medcalf, R. L., Johnston, L. A., Hovens, C. M., Jones, N. C., et al. (2015) · Brain · doi:10.1093/brain/awv053 · Cited by 159 · see citing works

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N. N., Starkov, A. A., Jové, M., Portero‐Otín, M., Launay, N., Pujol, A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu080 · Cited by 159 · see citing works

Invited review: Prion‐like transmission and spreading of tau pathology

Clavaguera, F., Hench, J., Goedert, M., & Tolnay, M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12197 · Cited by 156 · see citing works

Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease

Ittner, L. M., Ke, Y. D., & Götz, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014472 · Cited by 156 · see citing works

Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model

Lasagna‐Reeves, C. A., de Haro, M., Hao, S., Park, J., Rousseaux, M. W. C., Al‐Ramahi, I., Jafar‐Nejad, P., Vilanova-Velez, L., See, L., Maio, A. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.022 · Cited by 156 · see citing works

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works

Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease

Zumkehr, J., Rodríguez‐Ortiz, C. J., Cheng, D., Kieu, Z., Wai, T., Hawkins, C., Kilian, J., Lim, S., Medeiros, R., & Kitazawa, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.005 · Cited by 152 · see citing works

Identification of an Aggregation-Prone Structure of Tau

Elbaum-Garfinkle, S., & Rhoades, E. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305206m · Cited by 149 · see citing works

Lysosomal Dysfunction Promotes Cleavage and Neurotoxicity of Tau In Vivo

Khurana, V., Elson‐Schwab, I., Fulga, T. A., Sharp, K. A., Loewen, C. A., Mulkearns-Hubert, E. E., Tyynelä, J., Scherzer, C. R., & Feany, M. Β. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001026 · Cited by 148 · see citing works

Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease

Liu, C., Song, X., Nisbet, R. M., & Götz, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641902 · Cited by 145 · see citing works

Widespread tau seeding activity at early Braak stages

Furman, J. L., Vaquer‐Alicea, J., White, C. L., Cairns, N. J., Nelson, P. T., & Diamond, M. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1644-z · Cited by 142 · see citing works

Tau reduction prevents disease in a mouse model of <scp>D</scp> ravet syndrome

Gheyara, A. L., Ponnusamy, R., Djukic, B., Craft, R. J., Ho, K., Guo, W., Finucane, M. M., Sanchez, P. E., & Mucke, L. (2014) · Annals of Neurology · doi:10.1002/ana.24230 · Cited by 138 · see citing works

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

Hochgräfe, K., Sydow, A., Matenia, D., Cadinu, D., Könen, S., Petrova, O. M., Pickhardt, M., Goll, P., Morellini, F., Mandelkow�, E., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0204-4 · Cited by 137 · see citing works

The frontotemporal dementia mutation R406W blocks tau’s interaction with the membrane in an annexin A2–dependent manner

Gauthier‐Kemper, A., Weissmann, C., Golovyashkina, N., Sebö-Lemke, Z., Drewes, G., Gerke, V., Heinisch, J. J., & Brandt, R. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201007161 · Cited by 137 · see citing works

Loss of MAP Function Leads to Hippocampal Synapse Loss and Deficits in the Morris Water Maze with Aging

Ma, Q., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Kiosea, N., Nazari, S., Chen, P. P., Nothias, F., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3439-13.2014 · Cited by 135 · see citing works

How iPS cells changed the world

Scudellari, M. (2016) · Nature · doi:10.1038/534310a · Cited by 135 · see citing works

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI

Vos, S. J. B., van Rossum, I. A., Verhey, F. R. J., Knol, D. L., Soininen, H. S., Wahlund, L., Hampel, H. J., Tsolaki, M., Minthon, L., Frisoni, G. B., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318288690c · Cited by 133 · see citing works

Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity

Wegmann, S., Maury, E. A., Kirk, M. J., Saqran, L., Roe, A., DeVos, S. L., Nicholls, S., Fan, Z., Takeda, S., Cagsal‐Getkin, O., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592748 · Cited by 132 · see citing works

NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease

Corsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129 · see citing works

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease

Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 128 · see citing works

Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.

Liu, S.-J., Zheng, P., Wright, D. K., Dezsi, G., Braine, E., Nguyen, T., Corcoran, N. M., Johnston, L. A., Hovens, C. M., Mayo, J. N., et al. (2016) · Brain · doi:10.1093/brain/aww116 · Cited by 127 · see citing works

Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups

Soeda, Y., Yoshikawa, M., Almeida, O. F. X., Sumioka, A., Maeda, S., Osada, H., Kondoh, Y., Saito, A., Miyasaka, T., Kimura, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms10216 · Cited by 126 · see citing works

Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy

Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., Marotta, R., Xu, H., & Gasparini, L. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0082-7 · Cited by 126 · see citing works

Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach

Thomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123 · see citing works

PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans

Goedert, M., Baur, C.-P., Ahringer, J., Jakes, R., Hasegawa, M., Spillantini, M. G., Smith, M. J., & Hill, F. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.11.2661 · Cited by 123 · see citing works

Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression

Saito, T., Matsuba, Y., Yamazaki, N., Hashimoto, S., & Saido, T. C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1907-16.2016 · Cited by 121 · see citing works

The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome

Gunawardana, C. G., Mehrabian, M., Wang, X., Mueller, I., Lubambo, I., Jonkman, J. E. N., Wang, H., & Schmitt‐Ulms, G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.050724 · Cited by 118 · see citing works

PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE

Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 116 · see citing works

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Morimoto, B. H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., & on behalf of the AL-108-211 Study Investigators (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000348347 · Cited by 115 · see citing works

Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors

Kim, S., Choi, K. J., Cho, S., Yun, S., Jeon, J., Koh, Y. H., Song, J., Johnson, G. V. W., & Jo, C. (2016) · Scientific Reports · doi:10.1038/srep24933 · Cited by 113 · see citing works

Distinct Therapeutic Mechanisms of Tau Antibodies

Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · see citing works

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Wang, S. X., Acha, D., Shah, A. J., Hills, F. A., Roitt, I. M., Demosthenous, A., & Bayford, R. H. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.10.077 · Cited by 108 · see citing works

BAG3 facilitates the clearance of endogenous tau in primary neurons

Lei, Z., Brizzee, C. O., & Johnson, G. V. W. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.012 · Cited by 107 · see citing works

Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review

Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 107 · see citing works

Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals

Chen, F., David, D. C., Ferrari, A., & Götz, J. (2004) · Current Drug Targets · doi:10.2174/1389450043345236 · Cited by 107 · see citing works

Characteristics of Tau and Its Ligands in PET Imaging

Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 103 · see citing works

Revolutionizing Alzheimer's disease and clinical trials through biomarkers

Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102 · see citing works

Amyloid Precursor Protein (APP) Metabolites APP Intracellular Fragment (AICD), Aβ42, and Tau in Nuclear Roles

Multhaup, G., Huber, O., Buée, L., & Galas, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.677211 · Cited by 101 · see citing works

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100 · see citing works

Specific Calpain Inhibition by Calpastatin Prevents Tauopathy and Neurodegeneration and Restores Normal Lifespan in Tau P301L Mice

Rao, M. V., McBrayer, M. K., Campbell, J., Kumar, A., Hashim, A. T., Sershen, H. W., Stavrides, P. H., Ohno, M., Hutton, M., & Nixon, R. A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1132-14.2014 · Cited by 99 · see citing works

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer′s Disease Treatment

Martı́nez, A., Gil, C., & Pérez, D. I. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/280502 · Cited by 94 · see citing works

Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury–Induced Tauopathy in Transgenic Mice

Tran, H., Sanchez, L., & Brody, D. L. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182456aed · Cited by 92 · see citing works

Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration

Gentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., & Herskowitz, J. H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2336-15.2016 · Cited by 90 · see citing works

Calpain Inhibitor A-705253 Mitigates Alzheimer's Disease–Like Pathology and Cognitive Decline in Aged 3xTgAD Mice

Medeiros, R., Kitazawa, M., Chabrier, M. A., Cheng, D., Baglietto‐Vargas, D., Kling, A., Möller, A., Green, K. N., & LaFerla, F. M. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.020 · Cited by 89 · see citing works

HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila

Xiong, Y., Zhao, K., Wu, J., Xu, Z., Jin, S., & Zhang, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207586110 · Cited by 88 · see citing works

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies

Wagner, J., Krauß, S., Shi, S., Ryazanov, S., Steffen, J., Miklitz, C., Leonov, A., Kleinknecht, A., Göricke, B., Weishaupt, J. H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1483-3 · Cited by 87 · see citing works

Open questions for Alzheimer’s disease immunotherapy

Golde, T. E. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt233 · Cited by 85 · see citing works

Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia

Warmus, B. A., Sekar, D., McCutchen, E., Schellenberg, G., Roberts, R., McMahon, L. L., & Roberson, E. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3418-14.2014 · Cited by 84 · see citing works

The Dynamics and Turnover of Tau Aggregates in Cultured Cells

Guo, J., Buist, A., Soares, A. C., Callaerts, K., Calafate, S., Stevenaert, F., Daniels, J. P., Zoll, B. E., Crowe, A., Brunden, K. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712083 · Cited by 82 · see citing works

ptl-1, aCaenorhabditis elegansGene Whose Products Are Homologous to the τ Microtubule-Associated Proteins,

McDermott, J. B., Aamodt, S., & Aamodt, E. J. (1996) · Biochemistry · doi:10.1021/bi952646n · Cited by 80 · see citing works

Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau

Pavlova, À., Cheng, C., Kinnebrew, M., Lew, J., Dahlquist, F. W., & Han, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504415113 · Cited by 79 · see citing works

Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish

van Bebber, F., Paquet, D., Hruscha, A., Schmid, B., & Haass, C. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.023 · Cited by 77 · see citing works

NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy

Quraishe, S., Cowan, C. M., & Mudher, A. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.32 · Cited by 76 · see citing works

Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species

Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 73 · see citing works

Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein

Ma, Y., Chen, W., Zhang, X., Yu, L., Dong, W., Pan, S., Gao, S., Huang, X., & Zhang, L. (2016) · RNA Biology · doi:10.1080/15476286.2016.1185591 · Cited by 73 · see citing works

Rapamycin Ester Analog CCI-779/Temsirolimus Alleviates Tau Pathology and Improves Motor Deficit in Mutant Tau Transgenic Mice

Frédérick, C., Ando, K., Leroy, K., Héraud, C., Suain, V., Buée, L., & Brion, J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142097 · Cited by 69 · see citing works

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · see citing works

Age-related brain pathology in Octodon degu: Blood vessel, white matter and Alzheimer-like pathology

van Groen, T., Kadish, I., Popović, N., Popović, M., Caballero‐Bleda, M., Baño‐Otálora, B., Vivanco, P., Rol, M. A., & Madrid, J. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.008 · Cited by 64 · see citing works

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Congdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., González‐Calle, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 63 · see citing works

Tyrosine Nitration within the Proline-Rich Region of Tau in Alzheimer's Disease

Reyes, J. F., Fu, Y., Vana, L., Kanaan, N. M., & Binder, L. I. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.030 · Cited by 61 · see citing works

Protein with tau-like repeats regulates neuronal integrity and lifespan inC. elegans

Chew, Y. L., Fan, X., Götz, J., & Nicholas, H. (2013) · Journal of Cell Science · doi:10.1242/jcs.jcs124404 · Cited by 59 · see citing works

Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy

Xu, H. W., Rösler, T. W., Carlsson, T., Andrade, A., Fiala, O., Höllerhage, M., Oertel, W. H., Goedert, M., Aigner, A. M., & Höglinger, G. U. (2014) · Current Gene Therapy · doi:10.2174/156652321405140926160602 · Cited by 58 · see citing works

The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease

Flores-Rodríguez, P., Ontiveros‐Torres, M. Á., Cárdenas‐Aguayo, M. D. C., Luna‐Arias, J. P., Meraz‐Ríos, M. A., Viramontes‐Pintos, A., Harrington, C. R., Wischik, C. M., Mena, R., Florán, B., et al. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00033 · Cited by 58 · see citing works

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57 · see citing works

The unfolded protein response affects neuronal cell cycle protein expression: Implications for Alzheimer's disease pathogenesis

Hoozemans, J. J. M., Stieler, J., van Haastert, E. S., Veerhuis, R., Rozemüller, A. J. M., Baas, F., Eikelenboom, P., Arendt, T., & Scheper, W. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.01.013 · Cited by 56 · see citing works

The blood-brain barrier: Physiology and strategies for drug delivery

Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651 · see citing works

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation

Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516 · see citing works

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442 · see citing works

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310 · see citing works

Molecular Pathogenesis of the Tauopathies

Götz, J., Halliday, G., & Nisbet, R. M. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012936 · Cited by 276 · see citing works

Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria

Cummins, N., Tweedie, A., Zuryn, S., Bertran‐Gonzalez, J., & Götz, J. (2019) · The EMBO Journal · doi:10.15252/embj.201899360 · Cited by 267 · see citing works

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258 · see citing works

An Overview on the Clinical Development of Tau-Based Therapeutics

Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156 · see citing works

The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease

Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128 · see citing works

Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation

Saroja, S. R., Gorbachev, K., Julia, T., Goate, A. M., & Pereira, A. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108870119 · Cited by 75 · see citing works

Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer’s disease

Sen, T., Saha, P., Jiang, T., & Sen, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916895117 · Cited by 68 · see citing works

Neurotrophin receptor p75 mediates amyloid β-induced tau pathology

Shen, L.-L., Li, W.-W., Xu, Y.-L., Gao, S.-H., Xu, M.-Y., Bu, X.-L., Liu, Y.-H., Wang, J., Zhu, J., Zeng, F., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104567 · Cited by 59 · see citing works

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease

Qu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61 · see citing works

Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery

Bernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01030 · Cited by 49 · see citing works

Liquid − liquid phase separation of tau: Driving forces, regulation, and biological implications

Li, P., Chen, J., Wang, X., Su, Z., Gao, M., & Huang, Y. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106167 · Cited by 30 · see citing works

Short-term exposure to dim light at night disrupts rhythmic behaviors and causes neurodegeneration in fly models of tauopathy and Alzheimer's disease

Kim, M., Subramanian, M., Cho, Y.-H., Kim, G.-H., Lee, E., & Park, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.021 · Cited by 51 · see citing works

A Genomic Screen for Modifiers of Tauopathy Identifies Puromycin-Sensitive Aminopeptidase as an Inhibitor of Tau-Induced Neurodegeneration

Karsten, S. L., Sang, T.-K., Gehman, L. T., Chatterjee, S., Liu, J., Lawless, G. M., Sengupta, S., Berry, R. W., Pomakian, J., Oh, H. S., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.019 · Cited by 147 · see citing works

The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegenerationPreprint

Engstrom, A. K., Walker, A. C., Moudgal, R. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/745133

Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration

Jesús‐Cortés, H. D., Nogueras‐Ortiz, C. J., Gearing, M., Arnold, S. E., & Vega, I. E. (2012) · Neuroreport · doi:10.1097/wnr.0b013e32835982ce · Cited by 31 · see citing works

ApoE isoform– and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy

Seo, D.-O., O’Donnell, D., Jain, N., Ulrich, J. D., Herz, J., Li, Y., Lemieux, M., Cheng, J., Hu, H., Serrano, J. R., et al. (2023) · Science · doi:10.1126/science.add1236 · Cited by 254 · see citing works